Straits Times Index
3,307.90 -6.15 (-0.19%) Nikkei
38,946.93 -122.75 (-0.31%) Hang Seng
19,220.62 -415.60 (-2.12%) FTSE 100
8,416.45 -7.75 (-0.09%) Bitcoin USD
69,846.30 +1,665.26 (+2.44%) CMC Crypto 200
1,525.82 +37.28 (+2.50%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Previous close | 26.64 |
| Open | 25.87 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 25.87 - 25.87 |
| 52-week range | 25.04 - 32.76 |
| Volume | |
| Avg. volume | 8,548 |
| Market cap | 41.95B |
| Beta (5Y monthly) | 0.54 |
| PE ratio (TTM) | 44.60 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.26 (4.87%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
- CNW Group
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a Letter of Intent (LOI) for LIVTENCITY® (maribavir) for the treatment for adults with a post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies.1 With the LOI stage now complete, the provinces and territories may proceed in initiating their individual pro
- Business Wire
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
OSAKA, Japan & CAMBRIDGE, Mass., May 14, 2024--Takeda (TSE: 4502/NYSE:TAK) today announced that it will present data from its oncology pipeline and product portfolio at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2024, in Chicago, Ill.
- Business Wire
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
OSAKA, Japan & CAMBRIDGE, Mass & LAUSANNE, Switzerland, May 13, 2024--Takeda (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) today announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for the treatment of Alzheimer’s disease.
